Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NLST earnings next week should explode on anticipation of guidance on Hypercloud sales in 2010. Remember went from $1 to $7 in a few weeks on speculation of Hypercloud.
http://finance.yahoo.com/news/Netlist-Sets-Date-for-Fourth-prnews-2141779708.html?x=0&.v=1
NLST earnings next week should explode on anticipation of guidance on Hypercloud sales in 2010. Remember went from $1 to $7 in a few weeks on speculation of Hypercloud.
http://finance.yahoo.com/news/Netlist-Sets-Date-for-Fourth-prnews-2141779708.html?x=0&.v=1
SMTX:NASDAQ ($1.29) $.80 2010 EPS target:
The following summarizes why EMS manufacturer SMTX could earn $.60 - $.80 in 2010 and reach double digits:
HIGHER 2010 SALES: SMTX Reported $.03 EPS from continuing operations in Q3 2009 and said Q4 2009 will have higher sales. In 2010 sales will continue increasing as SMTX said several customers will ramp up sales.
COST REDUCTIONS:
SMTX has closed its Boston plant and transferred production to Mexico and China. This will improve efficiencies and GROSS MARGINS going forward. So SMTX's cost structure is now LOWER THAN EVER.
EMS SECTOR REBOUND:
The release of Windows 7 has spurred a dramatic rebound in the EMS and semiconductor industry. SMTX competitors like FLEX, MERX and SANM have posted double digit growth. MERX's sales increased over 23% last quarter and operating income increased 300%.
LOW FLOAT: SMTX has only 14 MM shares outstanding and a 12 million float so can move very fast to the upside.
POTENTIAL 2010 QUARTERLY EARNINGS:
Assuming a conservative 10% gross margin going forward and $55 MM quarterly sales ($65 Million was typical quarter before the recession):
Sales --------------------$55 Million
Gross Margin--------------$5.5 Million
Expenses:
Administrative expense----$2.7 million
Interest expense----------$0.5 million
Income = $2.3 Million OR $.16 per share
If SMTX gets back to historical $60 MM revenue per quarter, it should earn $.20 per share per quarter.
I think SMTX could be the next FSII and run to $3 in short order. Good luck and do your own DD for verification.
SMTX:NASDAQ ($1.29) $.80 2010 EPS target:
The following summarizes why EMS manufacturer SMTX could earn $.60 - $.80 in 2010 and reach double digits:
HIGHER 2010 SALES: SMTX Reported $.03 EPS from continuing operations in Q3 2009 and said Q4 2009 will have higher sales. In 2010 sales will continue increasing as SMTX said several customers will ramp up sales.
COST REDUCTIONS:
SMTX has closed its Boston plant and transferred production to Mexico and China. This will improve efficiencies and GROSS MARGINS going forward. So SMTX's cost structure is now LOWER THAN EVER.
EMS SECTOR REBOUND:
The release of Windows 7 has spurred a dramatic rebound in the EMS and semiconductor industry. SMTX competitors like FLEX, MERX and SANM have posted double digit growth. MERX's sales increased over 23% last quarter and operating income increased 300%.
LOW FLOAT: SMTX has only 14 MM shares outstanding and a 12 million float so can move very fast to the upside.
POTENTIAL 2010 QUARTERLY EARNINGS:
Assuming a conservative 10% gross margin going forward and $55 MM quarterly sales ($65 Million was typical quarter before the recession):
Sales --------------------$55 Million
Gross Margin--------------$5.5 Million
Expenses:
Administrative expense----$2.7 million
Interest expense----------$0.5 million
Income = $2.3 Million OR $.16 per share
If SMTX gets back to historical $60 MM revenue per quarter, it should earn $.20 per share per quarter.
I think SMTX could be the next FSII and run to $3 in short order. Good luck and do your own DD for verification.
SMTX:NASDAQ ($1.29) $.80 2010 EPS target:
The following summarizes why EMS manufacturer SMTX could earn $.60 - $.80 in 2010 and reach double digits:
HIGHER 2010 SALES: SMTX Reported $.03 EPS from continuing operations in Q3 2009 and said Q4 2009 will have higher sales. In 2010 sales will continue increasing as SMTX said several customers will ramp up sales.
COST REDUCTIONS:
SMTX has closed its Boston plant and transferred production to Mexico and China. This will improve efficiencies and GROSS MARGINS going forward. So SMTX's cost structure is now LOWER THAN EVER.
EMS SECTOR REBOUND:
The release of Windows 7 has spurred a dramatic rebound in the EMS and semiconductor industry. SMTX competitors like FLEX, MERX and SANM have posted double digit growth. MERX's sales increased over 23% last quarter and operating income increased 300%.
LOW FLOAT: SMTX has only 14 MM shares outstanding and a 12 million float so can move very fast to the upside.
POTENTIAL 2010 QUARTERLY EARNINGS:
Assuming a conservative 10% gross margin going forward and $55 MM quarterly sales ($65 Million was typical quarter before the recession):
Sales --------------------$55 Million
Gross Margin--------------$5.5 Million
Expenses:
Administrative expense----$2.7 million
Interest expense----------$0.5 million
Income = $2.3 Million OR $.16 per share
If SMTX gets back to historical $60 MM revenue per quarter, it should earn $.20 per share per quarter.
I think SMTX could be the next FSII and run to $3 in short order. Good luck and do your own DD for verification.
DRAM next CNLG Revolutionary product release any day:
DRAM ran to $5.50 just on speculation of XcelSAN release, which is long overdue:
Mr. Freeman continued, “We recently announced at the Storage Networking World trade show, a unique intelligent SAN optimization solution, XcelaSAN ®. XcelaSAN is the industry's first solution to deliver substantive application performance improvement to existing applications such as Oracle, SQL, Exchange and VMware. XcelaSAN augments existing storage systems by transparently applying intelligent caching algorithms that serve the most active block-level data from high-speed solid state storage, creating an intelligent, virtual solid state SAN. This breakthrough solution allows organizations to dramatically increase the performance of their existing business-critical applications without the costly hardware upgrades or over-provisioning of storage typically found in current solutions for increased performance. This product launch supports our corporate strategy to deliver data center solutions that optimize performance, leverage existing IT investments, and make measurable reductions in the total cost of ownership associated with these assets. On a limited basis this product is currently being shipped in our fiscal third quarter to select early install clients. We expect the product to be generally available early in 2010.
DRAM next CNLG Revolutionary product release any day:
DRAM ran to $5.50 just on speculation of XcelSAN release, which is long overdue:
Mr. Freeman continued, “We recently announced at the Storage Networking World trade show, a unique intelligent SAN optimization solution, XcelaSAN ®. XcelaSAN is the industry's first solution to deliver substantive application performance improvement to existing applications such as Oracle, SQL, Exchange and VMware. XcelaSAN augments existing storage systems by transparently applying intelligent caching algorithms that serve the most active block-level data from high-speed solid state storage, creating an intelligent, virtual solid state SAN. This breakthrough solution allows organizations to dramatically increase the performance of their existing business-critical applications without the costly hardware upgrades or over-provisioning of storage typically found in current solutions for increased performance. This product launch supports our corporate strategy to deliver data center solutions that optimize performance, leverage existing IT investments, and make measurable reductions in the total cost of ownership associated with these assets. On a limited basis this product is currently being shipped in our fiscal third quarter to select early install clients. We expect the product to be generally available early in 2010.
IPAD accessories: ZAGG gonna go on IPAD news also huge guidance for 2010
Taking these charges in the current quarter will allow management to establish expectations at a reasonable level, and improve our visibility for future earnings growth,” said President and CEO Robert G. Pedersen II. “CES (Consumer Electronics Show) was a great platform for the launch of many new lines and expanding the distribution of our existing lines. We remain optimistic about our growth prospects and expect 2010 to be a record year for the company both in revenues and earnings.”
IPAD accessories: ZAGG gonna go on IPAD news also huge guidance for 2010
Taking these charges in the current quarter will allow management to establish expectations at a reasonable level, and improve our visibility for future earnings growth,” said President and CEO Robert G. Pedersen II. “CES (Consumer Electronics Show) was a great platform for the launch of many new lines and expanding the distribution of our existing lines. We remain optimistic about our growth prospects and expect 2010 to be a record year for the company both in revenues and earnings.”
SMTX $1.50 + $.32 Potential $.80 Earnings in 2010:
The following summarizes why SMTX could earn $.60 - $.80 in 2010 and reach double digits:
HIGHER 2010 SALES: SMTX Reported $.03 EPS from continuing operations in Q3 2009 and said Q4 2009 will have higher sales:
http://finance.yahoo.com/news/SMTC-Repor...
In 2010 sales will continue increasing as SMTX said several customers will ramp up sales.
COST REDUCTIONS: SMTX has closed its Boston plant and transferred production to Mexico and China. This will improve efficiencies and GROSS MARGINS going forward. So SMTX's cost structure is now LOWER THAN EVER.
EMS SECTOR REBOUND: The release of Windows 7 has spurred a dramatic rebound in the EMS and semiconductor industry. SMTX competitors like FLEX, MERX and SANM have posted double digit growth. MERX's sales increased over 23% last quarter and operating income increased 300%.
LOW FLOAT: SMTX has only 14 MM shares outstanding and a 12 million float so can move very fast to the upside.
POTENTIAL 2010 QUARTERLY EARNINGS:
Assuming a conservative 10% gross margin going forward and $55 MM quarterly sales ($65 Million was typical quarter before the recession):
Sales --------------------$55 Million
Gross Margin--------------$5.5 Million
Expenses:
Administrative expense----$2.7 million
Interest expense----------$0.5 million
Income = $2.3 Million OR $.16 per share
If SMTX gets back to historical $60 MM revenue per quarter, it should earn $.20 per share per quarter.
I think SMTX could be the next FSII and run to $3 in short order. Good luck and do your own DD for verification.
SMTX $1.50 + $.32 Potential $.80 Earnings in 2010:
The following summarizes why SMTX could earn $.60 - $.80 in 2010 and reach double digits:
HIGHER 2010 SALES: SMTX Reported $.03 EPS from continuing operations in Q3 2009 and said Q4 2009 will have higher sales:
http://finance.yahoo.com/news/SMTC-Repor...
In 2010 sales will continue increasing as SMTX said several customers will ramp up sales.
COST REDUCTIONS: SMTX has closed its Boston plant and transferred production to Mexico and China. This will improve efficiencies and GROSS MARGINS going forward. So SMTX's cost structure is now LOWER THAN EVER.
EMS SECTOR REBOUND: The release of Windows 7 has spurred a dramatic rebound in the EMS and semiconductor industry. SMTX competitors like FLEX, MERX and SANM have posted double digit growth. MERX's sales increased over 23% last quarter and operating income increased 300%.
LOW FLOAT: SMTX has only 14 MM shares outstanding and a 12 million float so can move very fast to the upside.
POTENTIAL 2010 QUARTERLY EARNINGS:
Assuming a conservative 10% gross margin going forward and $55 MM quarterly sales ($65 Million was typical quarter before the recession):
Sales --------------------$55 Million
Gross Margin--------------$5.5 Million
Expenses:
Administrative expense----$2.7 million
Interest expense----------$0.5 million
Income = $2.3 Million OR $.16 per share
If SMTX gets back to historical $60 MM revenue per quarter, it should earn $.20 per share per quarter.
I think SMTX could be the next FSII and run to $3 in short order. Good luck and do your own DD for verification.
SMTX $1.50 + $.32 Potential $.80 Earnings in 2010:
The following summarizes why SMTX could earn $.60 - $.80 in 2010 and reach double digits:
HIGHER 2010 SALES: SMTX Reported $.03 EPS from continuing operations in Q3 2009 and said Q4 2009 will have higher sales:
http://finance.yahoo.com/news/SMTC-Repor...
In 2010 sales will continue increasing as SMTX said several customers will ramp up sales.
COST REDUCTIONS: SMTX has closed its Boston plant and transferred production to Mexico and China. This will improve efficiencies and GROSS MARGINS going forward. So SMTX's cost structure is now LOWER THAN EVER.
EMS SECTOR REBOUND: The release of Windows 7 has spurred a dramatic rebound in the EMS and semiconductor industry. SMTX competitors like FLEX, MERX and SANM have posted double digit growth. MERX's sales increased over 23% last quarter and operating income increased 300%.
LOW FLOAT: SMTX has only 14 MM shares outstanding and a 12 million float so can move very fast to the upside.
POTENTIAL 2010 QUARTERLY EARNINGS:
Assuming a conservative 10% gross margin going forward and $55 MM quarterly sales ($65 Million was typical quarter before the recession):
Sales --------------------$55 Million
Gross Margin--------------$5.5 Million
Expenses:
Administrative expense----$2.7 million
Interest expense----------$0.5 million
Income = $2.3 Million OR $.16 per share
If SMTX gets back to historical $60 MM revenue per quarter, it should earn $.20 per share per quarter.
I think SMTX could be the next FSII and run to $3 in short order. Good luck and do your own DD for verification.
Blog: CRXX $1.05 85% FDA approval chance Feb. 22
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_L/threadview?m=tm&bn=27758&tid=18383&mid=18383&tof=4&frt=2
DYNT:NASDAQ $1.06 Blowout earnings Monday
DYNT recently spiked to $1.44 on the pre announced earnings. Actual earnings announced Monday. DYNT could be a 10 bagger. Signed 3 major distribution contracts in last 6 weeks. Look at the guidance in the PR, he said December was very strong and "velocity will continue to increase".
http://finance.yahoo.com/news/Dynatronics-Announces-prnews-3499092147.html?x=0&.v=1
DYNT:NASDAQ $1.06 Blowout earnings Monday
DYNT recently spiked to $1.44 on the pre announced earnings. Actual earnings announced Monday. DYNT could be a 10 bagger. Signed 3 major distribution contracts in last 6 weeks. Look at the guidance in the PR, he said December was very strong and "velocity will continue to increase".
http://finance.yahoo.com/news/Dynatronics-Announces-prnews-3499092147.html?x=0&.v=1
DYNY Blowout earnings Monday
DYNT recently spiked to $1.44 on the pre announced earnings. Actual earnings announced Monday. DYNT could be a 10 bagger. Signed 3 major distribution contracts in last 6 weeks. Look at the guidance in the PR, he said December was very strong and "velocity will continue to increase".
http://finance.yahoo.com/news/Dynatronics-Announces-prnews-3499092147.html?x=0&.v=1
CRXX:NASDAQ next GNVC $1.22 + $.16 Slam dunk FDA approval in 3 weeks
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_C/threadview?m=tm&bn=27150&tid=2256&mid=2256&tof=10&frt=1
GNVC went form $1 to 43 in a few weeks. CRXX is far better. Looking for $3 by FDA approval date Feb 22.
CRXX:NASDAQ next GNVC $1.22 + $.16 Slam dunk FDA approval in 3 weeks
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_C/threadview?m=tm&bn=27150&tid=2256&mid=2256&tof=10&frt=1
GNVC went form $1 to 43 in a few weeks. CRXX is far better. Looking for $3 by FDA approval date Feb 22.
SMTX:NASDAQ +30% $1.52 $3.50 short term target:
DD Summary- Potential $.80 Earnings in 2010:
The following summarizes why SMTX could earn $.60 - $.80 in 2010 and reach double digits:
HIGHER 2010 SALES: SMTX Reported $.03 EPS from continuing operations in Q3 2009 and said Q4 2009 will have higher sales:
http://finance.yahoo.com/news/SMTC-Repor...
In 2010 sales will continue increasing as SMTX said several customers will ramp up sales.
COST REDUCTIONS: SMTX has closed its Boston plant and transferred production to Mexico and China. This will improve efficiencies and GROSS MARGINS going forward. So SMTX's cost structure is now LOWER THAN EVER.
EMS SECTOR REBOUND: The release of Windows 7 has spurred a dramatic rebound in the EMS and semiconductor industry. SMTX competitors like FLEX, MERX and SANM have posted double digit growth. MERX's sales increased over 23% last quarter and operating income increased 300%.
LOW FLOAT: SMTX has only 14 MM shares outstanding and a 12 million float so can move very fast to the upside.
POTENTIAL 2010 QUARTERLY EARNINGS:
Assuming a conservative 10% gross margin going forward and $55 MM quarterly sales ($65 Million was typical quarter before the recession):
Sales --------------------$55 Million
Gross Margin--------------$5.5 Million
Expenses:
Administrative expense----$2.7 million
Interest expense----------$0.5 million
Income = $2.3 Million OR $.16 per share
If SMTX gets back to historical $60 MM revenue per quarter, it should earn $.20 per share per quarter.
I think SMTX could be the next FSII and run to $3 in short order. Good luck and do your own DD for verification.
SMTX:NASDAQ $1.01 $.05 EPS this quarter very doable.
An old favorite, SMTX, is cheapest NASDAQ laggard in a hot sector, contract electronics manufacturing.
SMTX Reported $.03 EPS from continuing operations last quarter and said this quarter will have higher sales:
http://finance.yahoo.com/news/SMTC-Reports-Third-Quarter-prnews-2693727153.html?x=0&.v=11
If SMTX gets back to historical $60 MM revenue per quarter, it should earn $.15 per share per quarter.
I think SMTX could be the next FSII and run to $3. Only 14 MM shares OS.
Look at comparables trades at 0.06 PS ratio.
http://finance.yahoo.com/q/co?s=SMTX
SMTX $1.01 $.05 EPS this quarter very doable.
An old favorite, SMTX, is cheapest NASDAQ laggard in a hot sector, contract electronics manufacturing.
SMTX Reported $.03 EPS from continuing operations last quarter and said this quarter will have higher sales:
http://finance.yahoo.com/news/SMTC-Reports-Third-Quarter-prnews-2693727153.html?x=0&.v=11
If SMTX gets back to historical $60 MM revenue per quarter, it should earn $.15 per share.
I think SMTX could be the next FSII and run to $3. Only 14 MM shares OS.
Look at comparables trades at 0.06 PS ratio.
http://finance.yahoo.com/q/co?s=SMTX
SMTX $.95 +$.07 expect $.05 EPS this quarter
SMTX is cheapest NASDAQ laggard in a hot sector, contract electronics manufacturing. Reported $.03 EPS from continuing operations last quarter and said this quarter will have higher sales. I think SMTX could be the next FSII and run to $3. Only 14 MM shares OS.
Look at comparables trades at 0.06 PS ratio.
http://finance.yahoo.com/q/co?s=SMTX
SMTX $.95 +$.07 expect $.05 EPS this quarter
SMTX is cheapest NASDAQ laggard in a hot sector, contract electronics manufacturing. Reported $.03 EPS from continuing operations last quarter and said this quarter will have higher sales. I think SMTX could be the next FSII and run to $3. Only 14 MM shares OS.
Look at comparables trades at 0.06 PS ratio.
http://finance.yahoo.com/q/co?s=SMTX
LUNA doubler in 10 days:
LUNA is a biotech company with hundreds of patents. $35 MM in annual sales, 10 MM float trading for $2.13.
Historically, LUNA traded in the $6 - $8 range before it had to file bankruptcy protection due to a patent suit WITH HNSN. THE SUIT WAS SETTLED AND LUNA WILL EMERGE FROM BANKRUPTCY ON JANUARY 12 WHEN THE JUGDE APPROVES THE HNSN LUNA SETTLEMENT.
LUNA's core business is cash flow positive. Comparable companies in the filed trade at 5 x sales. With the lawsuit settled I expect LUNA to be back over $5 by February.
LUNA doubler in 10 days:
LUNA is a biotech company with hundreds of patents. $35 MM in annual sales, 10 MM float trading for $2.13.
Historically, LUNA traded in the $6 - $8 range before it had to file bankruptcy protection due to a patent suit WITH HNSN. THE SUIT WAS SETTLED AND LUNA WILL EMERGE FROM BANKRUPTCY ON JANUARY 12 WHEN THE JUGDE APPROVES THE HNSN LUNA SETTLEMENT.
LUNA's core business is cash flow positive. Comparable companies in the filed trade at 5 x sales. With the lawsuit settled I expect LUNA to be back over $5 by February.
LUNA doubler in 10 days:
LUNA is a biotech company with hundreds of patents. $35 MM in annual sales, 10 MM float trading for $2.13.
Historically, LUNA traded in the $6 - $8 range before it had to file bankruptcy protection due to a patent suit WITH HNSN. <B>THE SUIT WAS SETTLED AND LUNA WILL EMERGE FROM BANKRUPTCY ON JANUARY 12 WHEN THE JUGDE APPROVES THE HNSN LUNA SETTLEMENT.</B>
LUNA's core business is cash flow positive. Comparable companies in the filed trade at 5 x sales. With the lawsuit settled I expect LUNA to be back over $5 by February.
DRAM is gonna go Ballistic $3.55
LTXC ACLS SMOD FSII, list goes on and on.
DRAM next. 8 MM float was $5.4 a few weeks ago.
HCLS $1.05 exloding Insiders bought Big at $2.57
http://finance.yahoo.com/q/it?s=HLCS
HCLS $1.05 exloding Insiders bought Big at $2.57
http://finance.yahoo.com/q/it?s=HLCS
HCLS $1.05 exloding Insiders bought Big at $2.57
http://finance.yahoo.com/q/it?s=HLCS
MRNA Exploding $1.05 CEO said Partnership by year end:
CEO French at RNAI arranged that billion dollar buyout by Merck, now is taking MRNA, a company that was deep in debt and with nothing, to a no debt company with a port that is better than RNAI's when it got bought out for a billion. French said at the cc a month ago that he was not worried in the least about the nasdaq requirment of over a $50 m market cap. That means at least $1.30 or so SOON. Also said he had one smaller collaborative deal done, and another much larger one almost done. He has yet to announce either. When he does, multi dollars coming imo. Monday???
In November CEO said a deal will be announced BEFORE YEAR END:
http://www.genomeweb.com/rnai/mdrna-eyes-second-%E2%80%98early-collaborative-effort%E2%80%99-year-end-large-alliance-2010
MRNA Exploding $1.05 CEO said Partnership by year end:
CEO French at RNAI arranged that billion dollar buyout by Merck, now is taking MRNA, a company that was deep in debt and with nothing, to a no debt company with a port that is better than RNAI's when it got bought out for a billion. French said at the cc a month ago that he was not worried in the least about the nasdaq requirment of over a $50 m market cap. That means at least $1.30 or so SOON. Also said he had one smaller collaborative deal done, and another much larger one almost done. He has yet to announce either. When he does, multi dollars coming imo. Monday???
In November CEO said a deal will be announced BEFORE YEAR END:
http://www.genomeweb.com/rnai/mdrna-eyes-second-%E2%80%98early-collaborative-effort%E2%80%99-year-end-large-alliance-2010
MRNA Exploding $1.05 CEO said Partnership by year end:
CEO French at RNAI arranged that billion dollar buyout by Merck, now is taking MRNA, a company that was deep in debt and with nothing, to a no debt company with a port that is better than RNAI's when it got bought out for a billion. French said at the cc a month ago that he was not worried in the least about the nasdaq requirment of over a $50 m market cap. That means at least $1.30 or so SOON. Also said he had one smaller collaborative deal done, and another much larger one almost done. He has yet to announce either. When he does, multi dollars coming imo. Monday???
In November CEO said a deal will be announced BEFORE YEAR END:
http://www.genomeweb.com/rnai/mdrna-eyes-second-%E2%80%98early-collaborative-effort%E2%80%99-year-end-large-alliance-2010
NEXM:NASDAQ $.38 Cash flow Positive Drig stock
IMO NEXM is the most undervalued NASDA biotech:
-Just aquired Bioquaint a CASH FLOW POSITIVE DRUG COMPANY with 20% annual growth. I know NO other cash flow positive driug company on NASDAQ below $1.
-Only 95 MM shares Outstanding.
-Just received approval to stay on NASDAQ until March when I believe they will be way over $1.
-In last earnings call the said they would announce a Canadian drug partner before year end.
Compare market caps of some NASDAQ small penny biotechs and you can see why NEXM is such a HUGE BARGAIN:
DSCO:NASDAQ $75 MM market cap cash flow negative
GNVC:NASDAQ $90 MM market cap cash flow negative
NEXM:NASDAQ $35 MM market cap CASH FLOW POSITIVE
Here is excerpt from aquisition PR.
Commenting on today’s news, Ms. Liu stated, “We look forward to welcoming the Bio-Quant team as a NexMed subsidiary. Through this transaction, NexMed acquires a revenue generating, cash flow positive business which has grown over 250% in the past five years and is continuing to grow at present. Moreover, we will gain preclinical capabilities, add valuable licensing expertise and be able to leverage Bio-Quant’s existing relationships with key pharmaceutical companies – all of which will aid in the continued development and the ultimate commercialization of our products under development.”
NEXM:NASDAQ $.38 Cash flow Positive Drig stock
IMO NEXM is the most undervalued NASDA biotech:
-Just aquired Bioquaint a CASH FLOW POSITIVE DRUG COMPANY with 20% annual growth. I know NO other cash flow positive driug company on NASDAQ below $1.
-Only 95 MM shares Outstanding.
-Just received approval to stay on NASDAQ until March when I believe they will be way over $1.
-In last earnings call the said they would announce a Canadian drug partner before year end.
Compare market caps of some NASDAQ small penny biotechs and you can see why NEXM is such a HUGE BARGAIN:
DSCO:NASDAQ $75 MM market cap cash flow negative
GNVC:NASDAQ $90 MM market cap cash flow negative
NEXM:NASDAQ $35 MM market cap CASH FLOW POSITIVE
Here is excerpt from aquisition PR.
Commenting on today’s news, Ms. Liu stated, “We look forward to welcoming the Bio-Quant team as a NexMed subsidiary. Through this transaction, NexMed acquires a revenue generating, cash flow positive business which has grown over 250% in the past five years and is continuing to grow at present. Moreover, we will gain preclinical capabilities, add valuable licensing expertise and be able to leverage Bio-Quant’s existing relationships with key pharmaceutical companies – all of which will aid in the continued development and the ultimate commercialization of our products under development.”
NEXM:NASDAQ $.38 Cash flow Positive Drig stock
IMO NEXM is the most undervalued NASDA biotech:
-Just aquired Bioquaint a CASH FLOW POSITIVE DRUG COMPANY with 20% annual growth. I know NO other cash flow positive driug company on NASDAQ below $1.
-Only 95 MM shares Outstanding.
-Just received approval to stay on NASDAQ until March when I believe they will be way over $1.
-In last earnings call the said they would announce a Canadian drug partner before year end.
Compare market caps of some NASDAQ small penny biotechs and you can see why NEXM is such a HUGE BARGAIN:
DSCO:NASDAQ $75 MM market cap cash flow negative
GNVC:NASDAQ $90 MM market cap cash flow negative
NEXM:NASDAQ $35 MM market cap CASH FLOW POSITIVE
Here is excerpt from aquisition PR.
Commenting on today’s news, Ms. Liu stated, “We look forward to welcoming the Bio-Quant team as a NexMed subsidiary. Through this transaction, NexMed acquires a revenue generating, cash flow positive business which has grown over 250% in the past five years and is continuing to grow at present. Moreover, we will gain preclinical capabilities, add valuable licensing expertise and be able to leverage Bio-Quant’s existing relationships with key pharmaceutical companies – all of which will aid in the continued development and the ultimate commercialization of our products under development.”
NEXM:NASDAQ $.41 Copmletes aquisition just before close. Now a CASH FLOW POSITIVE DRUG STOCK
http://finance.yahoo.com/news/NexMed-Inc-to-Acquire-bw-4269777532.html?x=0&.v=1
Not many cash flow positive drug stocks below $2.
NEXM:NASDAQ $.41 Copmletes aquistion just before close. Now a CASH FLOW POSITIVE DRUG STOCK
http://finance.yahoo.com/news/NexMed-Inc-to-Acquire-bw-4269777532.html?x=0&.v=1
Not many cash flow positive drug stocks below $2.
CYCC: SNSS dropped a Nuclear bomb on shorts after hours
Reuters article
SNSS basically said buyout or partnership.
NO need for dilutive financing.
SNSS and CYCC both $3 + soon.
CYCC double bext week: SNSS dropped a Nuclear bomb on shorts after hours
Reuters article
SNSS basically said buyout or partnership.
NO need for dilutive financing.
SNSS and CYCC both $3 + soon. Leukemia breaktrhough drugs.